Abcellera Biologics Inc (ABCL)

$11.43 -0.14 (-1.21%)
Market Cap 3.55B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 2,019,200
Avg Vol 7,863,198
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 35%
Beta 1.32
Analysts Strong Sell
Price Target $17.12

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
doc_gk
doc_gk Sep. 5 at 4:13 PM
$ABCL This is going to be a banger .....
0 · Reply
UncleTomFlorida
UncleTomFlorida Sep. 4 at 8:28 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 7:34 PM
$ABCL CARL and MANAGEMENT know what they are doing! Don’t MISS OUT! I’m adding every chance I get! The Shorts attacked us for OVER 5 years and raised so much FUD!! They have NO IDEA what’s in play for them! They are going to 🔥 🔥 🔥!! This has been PRECISELY and STRATEGICALLY ORCHESTRATED to burn the SHORT’s!! We about to SQUEEZE baby $15-20’ss. Can you imagine we get the PHASE II 12 week data AFTER Hours or just right before the CONFERENCE in a few days!!!!! BOOM! 🤯
3 · Reply
UncleTomFlorida
UncleTomFlorida Sep. 4 at 7:30 PM
$ABCL $PLTR etc. I now own just a handful of stocks. Some of these are targets for the short sellers. While on a daily basis, that is an irritant. However, when one of my stocks gets hammered, I just buy more. I only sell when the stock goes long term & thus tax free. And then only when my monthly income isn’t enough for monthly expenses. That happens 2-3 months a year. Dividend paying stocks and short term profits are strictly for the IRA’s. I see the dips and troughs, which are pretty much predictable, as a way to get rich at the Shorties‘ expense. The last time I did the math, I could see a weighted average portfolio return of 50%-73% over the next twelve months. https://x.com/i/grok/share/1fa3d2cc29c14a21bbb46f274e620b82
0 · Reply
8008track
8008track Sep. 4 at 7:23 PM
$ABCL will we get some tasty news after hours?
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 7:20 PM
$ABCL CARL Loves to DROP NEWS After hours on Friday’s! He will do it Again!! Can you imagine if he DROP’s Phase II Result the 12 week data (90days) OMG 😱!! On a HOLIDAY WEEKENDand the shorts 🔥 🔥 🔥 until Tuesday!!!
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 7:11 PM
$ABCL @Rastafari just added another 10,000 shares a lot going to be coming out any moment and then we got the conference in a few days. I’m so f****** EXCITED!!! What a gift at these prices! You would be a fool not to be adding. NICE BUYS! Beautiful Chart! GREAT CONSOLIDATION! We are going from Red to GREEN!! Here comes $12’ssss!!
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 6:59 PM
$ABCL NO DOUBT! With all the GREAT NEWS 📰 that came this week!! More EXPECTED after hours today!! You know Carl loves to release news on FRIDAY’s after hours. With the recent Purchase of $30,000,000 MILLION from Blackrock Inc of ABCL SHARES this week adding to their $15,000 million stake!! Something is DEFINITELY UP!! 💯 ABCL also released at that same MOMENT they have a CONFERENCE in a FEW DAYS! Coincidence?!! Hell NO!! Expecting something HUGE After hours DEFINITELY before the CONFERENCE in a few days’s!! Management bought over $2,000,000 in the Open Market recently $11’s for 1 REASON only SOMETHING BIG is about to DROP!!! I’m expecting ABCL 575 that Carl said would come out this Quarter. I’m also thinking that the 12 week (90 days) DATA on phase II results is what they are going to release before the conference or during! What a BANGER that would be ‼️❣️ With Short Interest being at $43,000,000 we would SQUEEZE baby to an ALL TIME NEW HIGH! ABCL heading to $20-$25’s this month!!
0 · Reply
ayman1245
ayman1245 Sep. 4 at 6:21 PM
$ABCL can this reach 20 dollar brothers
2 · Reply
JennyRowes
JennyRowes Sep. 4 at 3:19 PM
$ABCL long weekend. all money managers are in the hamptons. the game starts again next week
0 · Reply
Latest News on ABCL
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

Sep 2, 2026, 4:05 PM EDT - 3 days ago

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

AbCellera rises 17.0%

2026-08-25T16:06:05.000Z - 11 days ago

AbCellera rises 17.0%

AbCellera rises 10.7%

2026-08-25T14:06:36.000Z - 11 days ago

AbCellera rises 10.7%

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

Aug 13, 2026, 12:05 AM EDT - 23 days ago

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

AbCellera announces $200M common stock, warrants offering

2026-08-11T20:05:47.000Z - 25 days ago

AbCellera announces $200M common stock, warrants offering

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aug 11, 2026, 4:01 PM EDT - 25 days ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

AbCellera price target raised to $30 from $12 at Truist

2026-08-11T13:35:37.000Z - 25 days ago

AbCellera price target raised to $30 from $12 at Truist

AbCellera price target raised to $25 from $13 at JonesResearch

2026-08-10T19:55:32.000Z - 26 days ago

AbCellera price target raised to $25 from $13 at JonesResearch

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 26 days ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 26 days ago

AbCellera Biologics Transcript: Study result

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 26 days ago

AbCellera Biologics Press release: Study result

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 26 days ago

AbCellera Biologics Slides: Study result

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:23 AM EDT - 26 days ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

Aug 10, 2026, 7:13 AM EDT - 26 days ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

2026-08-10T11:11:27.000Z - 26 days ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 10, 2026, 7:00 AM EDT - 26 days ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

Aug 7, 2026, 4:30 PM EDT - 4 weeks ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 4 weeks ago

AbCellera price target raised to $9 from $8 at Stifel

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

2026-08-06T12:12:02.000Z - 4 weeks ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Slides: Q2 2026

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Earnings release: Q2 2026

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Quarterly report: Q2 2026

AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 4 weeks ago

AbCellera Reports Q2 2026 Business Results

AbCellera announces collaboration with Vertex Pharmaceuticals

2026-07-29T11:27:06.000Z - 5 weeks ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

Jul 29, 2026, 7:00 AM EDT - 5 weeks ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

2026-07-09T21:29:02.000Z - 1 month ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Jul 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 2 months ago

AbCellera apponts Lynn Seely to board of directors

LYEL

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jun 17, 2026, 7:43 AM EDT - 2 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 3 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026, 4:05 PM EDT - 3 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 7, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 1:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 17, 2026, 4:30 PM EDT - 5 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 6 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 6 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:45 PM EST - 7 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 7 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 8 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 12 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

doc_gk
doc_gk Sep. 5 at 4:13 PM
$ABCL This is going to be a banger .....
0 · Reply
UncleTomFlorida
UncleTomFlorida Sep. 4 at 8:28 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 7:34 PM
$ABCL CARL and MANAGEMENT know what they are doing! Don’t MISS OUT! I’m adding every chance I get! The Shorts attacked us for OVER 5 years and raised so much FUD!! They have NO IDEA what’s in play for them! They are going to 🔥 🔥 🔥!! This has been PRECISELY and STRATEGICALLY ORCHESTRATED to burn the SHORT’s!! We about to SQUEEZE baby $15-20’ss. Can you imagine we get the PHASE II 12 week data AFTER Hours or just right before the CONFERENCE in a few days!!!!! BOOM! 🤯
3 · Reply
UncleTomFlorida
UncleTomFlorida Sep. 4 at 7:30 PM
$ABCL $PLTR etc. I now own just a handful of stocks. Some of these are targets for the short sellers. While on a daily basis, that is an irritant. However, when one of my stocks gets hammered, I just buy more. I only sell when the stock goes long term & thus tax free. And then only when my monthly income isn’t enough for monthly expenses. That happens 2-3 months a year. Dividend paying stocks and short term profits are strictly for the IRA’s. I see the dips and troughs, which are pretty much predictable, as a way to get rich at the Shorties‘ expense. The last time I did the math, I could see a weighted average portfolio return of 50%-73% over the next twelve months. https://x.com/i/grok/share/1fa3d2cc29c14a21bbb46f274e620b82
0 · Reply
8008track
8008track Sep. 4 at 7:23 PM
$ABCL will we get some tasty news after hours?
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 7:20 PM
$ABCL CARL Loves to DROP NEWS After hours on Friday’s! He will do it Again!! Can you imagine if he DROP’s Phase II Result the 12 week data (90days) OMG 😱!! On a HOLIDAY WEEKENDand the shorts 🔥 🔥 🔥 until Tuesday!!!
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 7:11 PM
$ABCL @Rastafari just added another 10,000 shares a lot going to be coming out any moment and then we got the conference in a few days. I’m so f****** EXCITED!!! What a gift at these prices! You would be a fool not to be adding. NICE BUYS! Beautiful Chart! GREAT CONSOLIDATION! We are going from Red to GREEN!! Here comes $12’ssss!!
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 4 at 6:59 PM
$ABCL NO DOUBT! With all the GREAT NEWS 📰 that came this week!! More EXPECTED after hours today!! You know Carl loves to release news on FRIDAY’s after hours. With the recent Purchase of $30,000,000 MILLION from Blackrock Inc of ABCL SHARES this week adding to their $15,000 million stake!! Something is DEFINITELY UP!! 💯 ABCL also released at that same MOMENT they have a CONFERENCE in a FEW DAYS! Coincidence?!! Hell NO!! Expecting something HUGE After hours DEFINITELY before the CONFERENCE in a few days’s!! Management bought over $2,000,000 in the Open Market recently $11’s for 1 REASON only SOMETHING BIG is about to DROP!!! I’m expecting ABCL 575 that Carl said would come out this Quarter. I’m also thinking that the 12 week (90 days) DATA on phase II results is what they are going to release before the conference or during! What a BANGER that would be ‼️❣️ With Short Interest being at $43,000,000 we would SQUEEZE baby to an ALL TIME NEW HIGH! ABCL heading to $20-$25’s this month!!
0 · Reply
ayman1245
ayman1245 Sep. 4 at 6:21 PM
$ABCL can this reach 20 dollar brothers
2 · Reply
JennyRowes
JennyRowes Sep. 4 at 3:19 PM
$ABCL long weekend. all money managers are in the hamptons. the game starts again next week
0 · Reply
Biker68
Biker68 Sep. 4 at 3:08 PM
$ABCL Boring day. The americans are too good at creating jobs - that's why most tech are down. Abcellera is holding on well - perhaps because they are well funded and won't be particularly affected by the expected rate hike?
0 · Reply
Rastafari
Rastafari Sep. 4 at 1:46 PM
$ABCL Miss our Moon trader…..awfully quite! Need to energize the board!
1 · Reply
Ckkung71
Ckkung71 Sep. 4 at 1:14 PM
$ABCL Another flipper game day?
0 · Reply
MagicRon_
MagicRon_ Sep. 3 at 6:53 PM
$ABCL Come on Bullies - you got this - lets hold that GREEN !!!! PMSL
3 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 3 at 6:22 PM
$ABCL @Buying_Low_Selling_High @Kaykay610 KNOWLEDGE is POWER! I have DONE ✅ MY Due Diligence $ABCL • Fastest company ever to deliver an antibody drug against a new viral target – COVID-19. • 14 partner-initiated molecules already in the clinic with downstream economics. • Huge partnered pipeline behind those clinical programs. • Growing internal pipeline with multiple wholly owned programs moving toward the clinic. • ABCL635 just delivered the first major clinical validation of the internal platform. • 83% reduction in hot flash frequency vs 33% placebo. • Strong balance sheet, now strengthened by another $200M. • World-class infrastructure built to discover, develop and manufacture antibodies under one roof. • Years of investment are finally moving from building the platform → producing clinical assets. • And we’re still very early. This is JUST the Beginning!!
0 · Reply
Merlintrader
Merlintrader Sep. 3 at 6:04 PM
AbCellera ($ABCL): Hot-Flash Severity Improved 58% Versus 12% on Placebo in ABCL635 Phase 2 https://www.merlintrader.com/abcellera-biologics-stock-hub/
0 · Reply
snowPOW
snowPOW Sep. 3 at 6:03 PM
$ABCL https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-blood-cancer-drug-meets-late-stage-trial-goals-2026-09-03/
1 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 3 at 5:39 PM
@Buying_Low_Selling_High @Kaykay610 $ABCL I don’t care how rich you are no one drops over 550/k on something that moved up 77% in just over a month if they aren’t dead serious about their intentions. CARL said ABCL 575 data coming out this Quarter. They MUST KNOW the RESULTS already!! $20’sss by end of SEPTEMBER! MANAGEMENT buying in the $11’sss in the OPEN MARKET!!
1 · Reply
MagicRon_
MagicRon_ Sep. 3 at 4:56 PM
$ABCL LOL what happened to " we are running baby " 😄
2 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 3 at 4:24 PM
$ABCL @Buying_Low_Selling_High I have DONE ✅ my DUE DILIGENCE With ABCL. So Many years and Sleepless Nights doing RESEARCH and looking up files. I just like to STATE the FACTS 💯 as I SEE THEM! I’m not look around the bush kind of person…I’m going to tell you how it is STRAIGHT UP!!! Don’t let this ONE get AWAY from YOU!!
0 · Reply
Stocktradesmoon
Stocktradesmoon Sep. 3 at 4:09 PM
$ABCL I just have DONE MY DUE DILIGENCE with ABCL. It’s been BEEN a lot of HARD WORK and NIGHT’s! It’s been several years of research and going through files. I just state the FACTS 💯 as I see them!! Dont’t let this one ☝️ get AWAY from YOU!
0 · Reply
thumperino
thumperino Sep. 3 at 3:26 PM
$ABCL miniscule volume and we're running
1 · Reply